Department of General, Viszeral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany.
Surgery. 2010 Mar;147(3):331-8. doi: 10.1016/j.surg.2009.10.027. Epub 2009 Dec 11.
Whether patients with focal pancreatic lesions of benign or borderline pathology should be treated by extended central pancreatectomy rather than by extended classic resectional procedures, such as extended right and left resections, is controversial.
Between 1992 and 2007, 105 patients underwent operation for focal pancreatic lesions of borderline or benign neuroendocrine neoplasms, cystadenoma, intraductal papillary mucinous neoplasia (IPMN), and secondary metastasis. In all, 35 patients were subjected to extended central pancreatectomy, whereas the remaining 70 patients were treated by an extended classic right resection or an extended classic left resection. Groups were matched according to age, sex, and histopathology.
No peri-operative mortality occurred after extended central pancreatectomy and extended classic left resection (n = 35, each). Two (6%) patients died after extended classic right resection. Overall, in-hospital morbidity was 26% after extended central pancreatectomy, 43% after extended classic right resection, and 37% after extended classic left resection. After a median follow-up of 48 months, a local recurrence rate of 17% after extended central pancreatectomy was similar to the corresponding rates of 9% after extended classic left resection and 14% after extended classic right resection. Endocrine and exocrine impairment was less pronounced after extended central pancreatectomy (6% and 9%) than after extended classic left resection (34% and 29%) and extended classic right resection (28% and 24%; P < .05).
Extended central pancreatectomy for appropriate pancreatic neoplasms is associated with less peri-operative morbidity and mortality than after extended classic left and extended classic right resection. Long-term local recurrence after extended central pancreatectomy is similar to the recurrence rates after extended classic right and classic left resection. Our results suggest that appropriately selected patients will benefit from extended central pancreatectomy because of the maintenance of endocrine and exocrine function.
对于具有局灶性胰腺病变的患者,无论其病理学为良性还是交界性,是否应采用扩大的中央胰腺切除术治疗,而不是采用扩大的经典切除术(如扩大的右、左切除术)治疗,目前仍存在争议。
1992 年至 2007 年,有 105 例行手术治疗的局灶性胰腺交界性或良性神经内分泌肿瘤、囊腺瘤、导管内乳头状黏液性肿瘤(IPMN)和继发性转移的患者。其中 35 例行扩大的中央胰腺切除术,其余 70 例行扩大的经典右切除术或扩大的经典左切除术。根据年龄、性别和组织病理学对两组进行匹配。
扩大的中央胰腺切除术和扩大的经典左切除术(每组 35 例)均无围手术期死亡。经典右切除术有 2 例(6%)患者死亡。总的来说,扩大的中央胰腺切除术的院内并发症发生率为 26%,扩大的经典右切除术为 43%,扩大的经典左切除术为 37%。中位随访 48 个月后,扩大的中央胰腺切除术的局部复发率为 17%,与扩大的经典左切除术的 9%和扩大的经典右切除术的 14%相似。与扩大的经典左切除术(34%和 29%)和扩大的经典右切除术(28%和 24%)相比,扩大的中央胰腺切除术引起的内分泌和外分泌功能不全的程度较轻(分别为 6%和 9%)。
对于适当的胰腺肿瘤,扩大的中央胰腺切除术与扩大的经典左、右切除术相比,围手术期并发症和死亡率较低。扩大的中央胰腺切除术后的长期局部复发率与扩大的经典右和经典左切除术的复发率相似。我们的研究结果表明,适当选择的患者将从扩大的中央胰腺切除术获益,因为该手术可保留内分泌和外分泌功能。